Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rajeev Rajani

Adolescent Medicine Naples, FL Medical Doctor

NPI 1316038698 CMS profile 59734

6615 Hillway Cir, Suite 200, Naples, FL 34112

Open in the dashboard

General payments

$6,481

288 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rajeev Rajani of Naples, FL is reported in the CMS Open Payments database as having received $6,481 across 288 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Adolescent Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $376 13
2024 General $636 27
2023 General $1,227 44
2022 General $1,087 48
2021 General $971 52
2020 General $835 47
2019 General $1,350 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rajeev Rajani
  • Adolescent Medicine median
  • Middle half of Adolescent Medicine
  • National median

In program year 2025, general payments to Rajeev Rajani were reported at $376. Among 113 Adolescent Medicine profiles paid that year, the median was $165 and the middle half received between $61 and $402.

Show as a table
Year Rajeev Rajani Adolescent Medicine median Middle half National median
2019 $1,350 $151 $36–$708 $163
2020 $835 $123 $24–$337 $114
2021 $971 $155 $54–$620 $132
2022 $1,087 $158 $50–$556 $149
2023 $1,227 $170 $52–$612 $160
2024 $636 $182 $65–$431 $164
2025 $376 $165 $61–$402 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,260 57 payments
  2. Amgen Inc. $888 43 payments
  3. GlaxoSmithKline, LLC. $766 45 payments
  4. Novo Nordisk Inc $521 34 payments
  5. Janssen Pharmaceuticals, Inc $386 15 payments
  6. Medtronic, Inc. $314 2 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $308 9 payments
  8. Pfizer Inc. $197 11 payments
  9. Smith+Nephew, Inc. $173 4 payments
  10. Amarin Pharma Inc. $162 6 payments
  11. Other $1,507 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,350 282 payments
  2. Education $131 6 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $604 30 payments
  2. Repatha $518 27 payments
  3. Otezla $462 24 payments
  4. BREZTRI $450 15 payments
  5. SHINGRIX $435 25 payments
  6. TRELEGY ELLIPTA $376 22 payments
  7. Ozempic $347 22 payments
  8. COBALT DR MRI SURESCAN $314 2 payments
  9. RYBELSUS $305 18 payments
  10. XARELTO $265 14 payments
  11. Other $4,549 195 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 166 drugs

Part D claims

13,246

Median for Internal Medicine: 777

Drug cost

$1,107,307

Median for Internal Medicine: $73,373

Branded share of claims

16%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 142 $167,897
Jardiance Empagliflozin Brand 107 $155,271
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 11 $117,114
Ozempic Semaglutide Brand 73 $80,543
Xarelto Rivaroxaban Brand 62 $75,608
Trulicity Dulaglutide Brand 58 $71,018
Januvia Sitagliptin Phosphate Brand 51 $70,783
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 34 $43,031
Mounjaro Tirzepatide Brand 30 $30,987
Farxiga Dapagliflozin Propanediol Brand 21 $22,179

The 10 drugs with the highest cost, of 166 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$629,945

Of which drugs: $95,966

Medicare patients

1,060

Average age 78

Services billed

10,964

561 women, 499 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 34%
Diabetes 26%
Atrial fibrillation 21%
Cancer 21%
Chronic kidney disease 20%
Osteoporosis 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 47 4,502 $89,179
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 201 201 $4,402
Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 Office 17 17 $2,107
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 30 114 $83

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $145
$145 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $53
$53 30 —
XARELTO
  • Janssen Pharmaceuticals, Inc $39
$39 62 —
Otezla
  • Amgen Inc. $38
$38 — —
Repatha
  • Amgen Inc. $38
$38 16 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

288 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adolescent Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record